NCT02282826View on ClinicalTrials.gov

A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Progressive Multiple Sclerosis

Interventions

DRUG

GZ402668

Pharmaceutical form:solution Route of administration: intravenous

DRUG

placebo

Pharmaceutical form:solution Route of administration: intravenous

DRUG

GZ402668

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

placebo

Pharmaceutical form:solution Route of administration: subcutaneous

DRUG

acyclovir

Pharmaceutical form:tablet Route of administration: oral

Trial Locations (1)

10117

Investigational Site Number 276001, Berlin

All Listed Sponsors

lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02282826 - A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter